Antihypertensive therapy and incidence of type 2 diabetes in an elderly cohort.
Padwal
Raj
R
Division of General Internal Medicine, University of Alberta, Edmonton, Canada. rpadwal@ualberta.ca
Mamdani
Muhammad
M
Alter
David A
DA
Hux
Jan E
JE
Rothwell
Deanna M
DM
Tu
Karen
K
Laupacis
Andreas
A
D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001581:Benzothiadiazines; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced* / Q000453:epidemiology*; D004232:Diuretics; D005260:Female; D015577:Geriatric Assessment; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy*; D015994:Incidence; D008297:Male; D009864:Ontario / Q000453:epidemiology; D011336:Probability; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D018570:Risk Assessment; D017678:Sex Distribution; D049993:Sodium Chloride Symporter Inhibitors / Q000009:adverse effects / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001581:Benzothiadiazines; D002121:Calcium Channel Blockers; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors